依达拉奉对急性脑梗死患者血清基质金属蛋白酶9表达的影响

The Impact of Edaravone on Acute Cerebral Infarction and Its Serum Matrix Metalloproteinase-9's Expression

目的观察分析依达拉奉治疗急性脑梗死的疗效以及对急性脑梗死患者血清基质金属蛋白酶9(MMP-9)表达的影响。方法 100例急性脑梗死患者根据入院先后顺序随机分为治疗组(常规治疗+依达拉奉)和对照组(常规治疗)各50例,比较两组的疗效及MMP-9的变化情况。结果治疗组的总有效率高于对照组,两组神经功能缺损评分均降低,治疗组神经功能缺损评分降低明显,两组MMP-9的含量均明显降低,治疗组的MMP-9明显低于对照组(P<0.05)。结论依达拉奉治疗急性脑梗死疗效明显,可以降低MMP-9的水平,值得临床予以重视。

Objective To observe and analyze the edaravone treatment acute cerebral infarction and the impact on serum matrix metalloproteinase 9 （ MMP-9 ）＇ s expression. Methods All 100 patients with acute cerebral infarction were randomLy divided into treatment group （ conventional therapy ＋ edaravone ） and the control group （ conventional treatment ） 50 patients, and to compare the efficacy and MMP-9＇ s changes. Results The total effective rate of the treatment group was higher than the control group, two groups＇ neurological deficit score were lower, and the treatment group were significantly lower than the control group, two groups＇ MMP-9 levels were significantly lower, and the treatment group was significantly lower than the control group （P 〈 0.05 ）. Conclusion Edaravone treatment of acute cerebral infarction can significantly reduce the level of MMP-9, and it is worthy of attention.